Mizuho (NYSE:MFG) analysts maintained a Neutral rating on Revance Therapeutics (NASDAQ:RVNC), a $382 million market cap company, with a steady price target of $3.65. The firm's stance came in the wake ...
Yet "the bond market has not taken on board" the potential for 3% inflation in 2025, Steven Ricchiuto, chief economist at Mizuho Securities, wrote in a Monday client note. Even before December's ...
Geneos Wealth Management Inc. lessened its holdings in shares of The Clorox Company (NYSE:CLX – Free Report) by 8.3% during ...
Securities expressed a positive outlook on Welltower Inc. (NYSE:WELL), an $84 billion market cap healthcare REIT that has ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Mizuho Securities raised its recommendation on Vornado Realty Trust (NYSE:VNO) and Cousins Properties (NYSE:CUZ), and downgraded Kilroy Realty (NYSE:KRC), considering their geographic exposure and ...
This year’s winners from Mizuho Americas were: Serena Lin, Managing Director and Head of Agency Mortgage-Backed Securities Trading Desk for Excellence in Fix NEW YORK, Aug. 28, 2024 (GLOBE ...
Securities adjusted its outlook on Sage Therapeutics (NASDAQ:SAGE) shares, with analyst Vamil Divan increasing the price target to $9.00 from the previous $6.00, while maintaining a Neutral rating on ...
Qorvo (NASDAQ:QRVO) shares fell 0.5% in premarket trading on Friday, even as Mizuho Securities upped its earnings estimates on the involvement of activist investor Starboard Value. Mizuho analyst ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback